Clinical Trial Update: Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating zanubrutinib in participants with relapsed/refractory non-GCB type diffuse large B-cell lymphoma has completed, with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-11-08